Value Microcaps Zip Code Changers

[Potse]

ECGI(.151)...NowCardio introduction expected in Q4.....

I continue to hold my position in ECGI, and still expect to see prices well above the 20-cent level at some point. IMO, the 5-10 cent area looks reasonably attractive for entry/accumulation of both core and trading positions. If the company successfully executes on its current business plan, I am anticipating significant tradeable opportunities in the ECGI stock over the next 12+ months.

This week the company started putting updated business/financial presentations on the investors section of its website. It appears much of the final packaging design for the NowCardio system/product has been completed. The target time frame for the ramp-up of the BreastCare DTS business/product appears to be the first quarter of 2016. The anticipated blanket purchase orders mentioned in the business plan would represent annual revenues exceeding $20M.

Things should be getting a bit more interesting over the next quarter or two, as corporate events/milestones appear to be rapidly approaching. A large financing, increased media-related exposure and ECGI's commercialization/production of both NowCardio and BreastCare DTS could occur between now and early/mid 2016.

According to the guidance provided in press releases this month, regulatory certification/approvals of ECGI's NowCardio product are expected to occur in Q4. Market introduction of the product is expected before the end of 2015. NowCardio has significant design/performance advantages over existing technologies/products in the market.

A few items of interest from the company's recent press releases.....

1)

Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company, is pleased to announce that its Ambulatory Arrhythmia Monitoring System, NowCardio™, has successfully completed the first audit of compliance to Canadian Medical Devices Conformity Assessment System (CMDCAS) and ISO 13485:2003. The audit was conducted by a recognized registrar, BSI Group, and is a significant milestone towards both Health Canada and FDA certification. NowCardio™ is on track to receive regulatory certification and approvals in Q4 of 2015.

NowCardio™ is an advanced Ambulatory Arrhythmia Monitoring System that will be used to monitor, analyze, record, and transmit a patient's heart physiological data in real-time. NowCardio™ will be a world first where a cardiac monitoring system can offer dual-functionality of both Cardiac Holter Monitoring and Cardiac Loop Event Recording.

John Bentivoglio, Chief Executive Officer and President of Event Cardio Group, stated, "The audit was outside verification that the NowCardio™ certification is advancing as planned, and we anticipate releasing this innovative product to the market in late 2015."

http://www.otcmarkets.com/stock/ECGI/news/Event-Cardio-Group-Crosses-Major-Hurdle?id=113622&b=y

2)

President and CEO John Bentivoglio stated, "With the completion of this short term funding, we can now focus on our long term goals and negotiate with those groups that have expressed interest to best satisfy our long term funding requirement. Completion of a major funding will ensure the imminent production of BreastCare DTS™ at Ceres Technologies. We are looking forward to completion of the fully automated manufacturing line early in 2016. The fully automated manufacturing line will be capable of producing a high volume of BreastCare DTS™ devices for worldwide distribution. NowCardio™ certification is advancing as planned, and we anticipate releasing this innovative product to the market in late 2015."

http://www.otcmarkets.com/stock/ECGI/news/Event-Cardio-Group-Satisfies-Short-Term-Financing-Needs?id=113951&b=y

3)

Event Cardio Group, Inc. (OTCQB: ECGI), a leader in the development of cardiac monitoring and early detection of high-risk diseases, today announced the appointment of Julie Singleton as Chief Executive Officer of its BreastCare Division and to the Company's board of directors. Ms. Singleton currently serves as Chief Executive Officer at MedPac Asia Pacific PTY Ltd, of Australia, exclusive South East Asia Distributor of ECGI's BreastCare DTS ® and NowCardio.

"We are extremely pleased to have Julie, a luminary in the breast cancer awareness and media world, join our board and agree to actively serve as the CEO of our BreastCare Division," said John Bentivoglio, Chairman and CEO of Event Cardio Group. "Julie has been at the forefront of the early detection of Breast and other cancers for many years and we believe her first hand experiences in the field have paved the way for companies like Event Cardio Group to introduce medical technology advances. With an impressive list of accomplishments in law, management and business development, Julie will be a terrific addition to our board and a great CEO. We look forward to her contributions as we move forward with our media outreach and marketing efforts to create awareness among women of our noninvasive option for early detection of breast cancer using our BreastCare DTS ® technology."

http://www.otcmarkets.com/stock/ECGI/news/Event-Cardio-Group--Inc--Appoints-Cancer-Industry-Veteran--Julie-Singleton--as-Chief-Executive-Officer-of-Its-BreastCare-Division?id=114603&b=y